Alpha-1 Antitrypsin Deficiency (AATD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Alpha-1 Antitrypsin Deficiency (AATD) is an autosomal codominant genetic condition that can result in serious lung disease in adults and/or liver disease at any age. AATD occurs when the blood is deficient in a protein called Alpha-1 antitrypsin, or AAT. The liver mainly produces AAT, which primarily protects the lungs from increased protease activity. The responsible gene, SERPINA1, is located on the long arm of chromosome 14 (14q31–32.3).
- According to Thelansis disease modeling
data and literature review estimated, ~78000 patients with AATD in the
United States in the year 2020.
Thelansis’s “Alpha-1 Antitrypsin
Deficiency (AATD) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Alpha-1
Antitrypsin Deficiency (AATD) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Alpha-1 Antitrypsin Deficiency (AATD) across 8 MM market from the centre of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Alpha-1 Antitrypsin Deficiency (AATD) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment